CRYSTALLINE FORMS OF PENTAAZA MACROCYCLIC RING COMPLEX
The present disclosure provides polymorph forms of pentaaza macrocyclic ring Also provided are pharmaceutical compositions that include the provided polymorph forms and methods of using the provided polymorph forms and pharmaceutical compositions for the treatment of disease states.
1 . A Form V crystalline form of GC4419 according to the following formula:
having one or more characteristic XRPD (X-Ray Powder Diffraction) peaks as shown in FIG. 3 .
2 . A Form VI crystalline form of GC4419 according to the following formula:
having one or more characteristic XRPD peaks as shown in FIG. 9 .
3 . A Form VIII crystalline form of GC4419 according to the following formula:
having one or more characteristic XRPD peaks as shown in FIG. 6 .
4 . A Form XI crystalline form of GC4419 according to the following formula:
having one or more characteristic XRPD peaks as shown in FIG. 8 .
5 . A pharmaceutical composition comprising one or more of Form V GC4419, Form VI GC4419, Form VIII GC4419 and Form XI GC4419.
6 . A method of treating cancer comprising administering a composition of claim 5 and one or more pharmaceutically acceptable excipients to a patient in need thereof.
7 . A method of treating an inflammatory condition comprising administering a composition of claim 5 and one or more pharmaceutically acceptable excipients to a patient in need thereof.
8 . The method of claim 7 , wherein the inflammatory condition is oral mucositis.